ClinicalTrials.gg
Not yet recruitingNCT07270198PERSONALISEDKDUpdated Nov 19, 2026

Renal MRI and Advanced Biochemical Markers to Predict Progression in DKD Patients Treated With SGLT2i

An interventional study of MRI and Biochemical Analysis in Diabetic Kidney Disease (DKD), sponsored by Mario Negri Institute for Pharmacological Research. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Mario Negri Institute for Pharmacological Research · Not applicable, Interventional, and Basic science

How we know

Updated Nov 19, 2026First sites in Denmark and SpainStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies in Diabetic Nephropathies with a site in Denmark — 6 open to participants now, 6 under way, none of them phase 3. Diabetic Nephropathies · Denmark.

Planned enrollment
13th of 36
100 · median 61
Started
2026
the only one that year
No phase
6 of 42
1 open now
Registered
42nd of 42
by date

Among the 42 studies in Diabetic Nephropathies with a site in Denmark, this one is the 13th largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 42nd registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

6 of the 42 studies in Diabetic Nephropathies with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetic Nephropathies with a site in Denmark, or all of them as a file.
02

Study summary

This is a multicentre and multi-national non-pharmacological, uncontrolled interventional study conducted in a clinical practice setting in DKD patients with CKD stages G1 to G3 with moderate or severe risk of renal function decline in chronic treatment with SGLT2i.

The main aim of the study is to assess the independent role of baseline individual mpMRI markers (hemodynamic, oxygenation, microstructure, perfusion, and fat fraction) and biochemical markers of MMP-related pathways (MMP-10 and TIMP-1) in the prediction of chronic eGFR decline over 18 months in the above mentioned patients who are on chronic SGLT2i therapy.

Read the detailed description

Recent years have seen an exponential increase in the incidence and prevalence of chronic kidney disease (CKD). Diabetes Mellitus is the leading cause of CKD. Diabetic kidney disease (DKD) is clinically defined by the presence of reduced kidney function and/or increased albuminuria for at least three months in patients with diabetes. However, not all patients with diabetes develop DKD and not all patients with DKD follow the same trajectory. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently shown significant nephroprotective benefits, making them a first-line therapy in DKD. Although the mechanisms underlying SGLT2i nephroprotection are not fully understood, preliminary data suggest a long-term benefit on metabolic, haemodynamics, and/or kidney injury pathways. SGLT2i have also been shown to be nephroprotective in mouse models, attenuating renal fibrosis in diabetes. These promising results highlight the potential of SGLT2i to avert severe CKD-related events through early intervention, particularly in patients at higher risk of progression. However, clinical, and genetic factors may influence response to SGLT2i in patients with comorbid conditions and already receiving antidiabetic and antihypertensive drugs. Therefore, within a personalised medicine approach, it would be essential to early identify DKD patients with fast progressive decline in renal function, associated with increased morbidity and mortality, who may benefit the most from SGLT2i therapy. To achieve this, biomarkers with heightened specificity and sensitivity to disease progression and response to treatment are urgently needed.

Renal multiparametric MRI (mpMRI) has recently shown great potential to investigate renal structure, microstructure, and function, facilitating the diagnosis and monitoring of CKD progression and response to treatment. Recent studies showed the ability of decreased renal blood flow - assessed by arterial spin labelling (ASL) MRI - in detecting subclinical renal involvement in patients with type 2 diabetes. Blood oxygenation level dependent (BOLD)-MRI showed an acute effect on renal cortical oxygenation in response to SGLT2i treatment in type I diabetic patients with albuminuria. mpMRI shows potential to investigate and quantify renal and perirenal adipose tissue (fat fraction), that is thought to play a significant role on the renal involvement in diabetes and obesity. mpMRI has also shown its ability to monitor the effects of SGLT2i in type 2 diabetes.

Moreover, the hallmark of DKD pathogenesis is excessive accumulation of extracellular matrix (ECM) leading to thickening of the glomerular and tubular basement membranes, followed by mesangial expansion, sclerosis, and tubulointerstitial fibrosis. Dysregulated balance between levels of matrix metalloproteases (MMPs, involved in ECM degradation and hydrolysis) and their tissue inhibitors (TIMP) has been found in DKD patients, and altered serum and urine TIMP-1 levels have been linked with worsening glomerular lesions. MMP-10 null diabetic mice presented fewer mesangial expansion, renal macrophage infiltration and renal function impairment. These findings may support a deleterious kidney effect of MMP-10 in DKD.

To confirm and expand these single-centre findings, a more in-depth analysis of pathogenic mechanisms and a more accurate risk stratification are required in order to personalise the clinical management of DKD.

The PERSONALISE-DKD clinical study aims to use advanced biochemical and imaging biomarkers to characterize DKD patients at moderate or severe risk of renal disease progression who may get the greatest benefit from future clinical trials and targeted healthcare management interventions, potentially contributing to a change in the current clinical approach to a disease that represents the leading cause of advanced CKD.

03

Conditions studied

  • Diabetic Kidney Disease (DKD)
04

Who can participate

The criteria were revised on the registry on Nov 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (to be eligible to participate in this trial, an individual must meet all the following criteria):

  1. male and female subjects aged ≥18 years at time of screening;
  2. written prior to any study specific procedures;
  3. type 2 Diabetes Mellitus with DKD;
  4. CKD stage G1 to G3 (>30 ml/min calculated by the creatinine CKD-EPI 2009 equation) with moderate or severe risk of renal disease progression (according to KDIGO 2024 CKD guidelines, G1 and G2 with albuminuria >300 mg/g, G3a with albuminuria >30 mg/g, and G3b independently of albuminuria levels);
  5. ongoing SGLT2i treatment (e.g. canagliflozin, empagliflozin or dapagliflozin) for at least 1 month and no longer than 1 year, and stable RAS inhibitor therapy with ACE inhibitors and/or ARBs (or without RAS inhibitors in patients with specific for this medication) (Group 1) or SGLT2i-naïve subjects who have been prescribed this therapy as part of routine clinical practice prior to enrollment (Group 2).

Exclusion Criteria (an individual who meets any of the following criteria will be excluded from participation in this trial):

  1. Uncontrolled diabetes ( (A1C) > 8%; 64 mmol/mol);
  2. Contraindications to MRI including claustrophobia, pregnancy or breastfeeding, cardiac pacemakers, or other MRI-incompatible prostheses, or inability to undergo MRI;
  3. Any chronic clinical condition (e.g. history of ) other than CKD and related complications that may compromise study completion or affect data interpretation;
  4. Non-diabetic CKD: CKD highly suspected to be related with a different renal condition other than Diabetes Mellitus as the cause of CKD (i.e. glomerular disease, tubulo-interstitial nephritis, microangiopathic thrombotic disease, renovascular/ischemic kidney disease, etc);
  5. Active systemic diseases;
  6. Concomitant treatment with or any other agent;
  7. Chronic heart failure class III-IV according to (NYHA) classification at the screening visit;
  8. Intention to become pregnant within the next 2 years (female patients);
  9. Drug or alcohol abuse.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Patients

    Adult Diabetic Kidney Disease (DKD) patients with CKD stages G1 to G3 at moderate or severe risk of renal disease progression, receiving ongoing SGLT2i treatment (e.g. canagliflozin, empagliflozin or dapagliflozin) for at least 1 month and no longer than 1 year, and stable RAS inhibitor therapy with ACE inhibitors and/or ARBs (or without RAS inhibitors in patients with specific contraindications for this medication).

    Procedure: MRI and Biochemical Analysis

  • Experimental
    SGLT2i-naïve patients

    Adult patients with diabetic kidney disease (DKD), CKD stages G1-G3, at moderate or severe risk of renal disease progression, who are SGLT2i-naïve at the time of screening and have been prescribed SGLT2i therapy as part of routine clinical practice prior to study enrollment.

    Procedure: MRI and Biochemical Analysis

Interventions

  • ProcedureMRI and Biochemical Analysis

    Multiparametric non-contrast enhanced renal MRI and biochemical analysis to investigate MMP-related pathways (MMP-10 and TIMP-1 serum levels)

06

What researchers measure

Primary outcomes

  1. Estimated glomerular filtration rate (eGFR)

    EGFR estimation by CKD-EPI and EKFC equations (ml/min)

    Time frame: At day 0, at 1 month and at 18 months

  2. Matrix metalloproteases (MMPs) and their tissue inhibitors (TIMP)

    Serum levels of MMP-10 and TIMP-1 will be assessed in blood samples by commercial ELISA kits, according to the manufacturer's instructions (pg/ml)

    Time frame: At day 0, at 1 month and at 18 months

  3. Multiparametric kidney MRI

    Total kidney, cortical and medullary volumes (in mL)

    Time frame: At day 0, at 1 month and at 18 months

  4. Multiparametric kidney MRI

    Renal tissue oxygenation obtained by measuring the R2\* relaxation rate (in 1/ms)

    Time frame: At day 0, at 1 month and at 18 months

  5. Multiparametric kidney MRI

    Apparent diffusion coefficient (in cm2/s)

    Time frame: At day 0, at 1 month and at 18 months

  6. Multiparametric kidney MRI

    Renal tissue perfusion (in mL/100mL/min)

    Time frame: At day 0, at 1 month and at 18 months

  7. Multiparametric kidney MRI

    Renal blood flow (in mL/min)

    Time frame: At day 0, at 1 month and at 18 months

  8. Multiparametric kidney MRI

    T1 and T2 relaxation times (in ms)

    Time frame: At day 0, at 1 month and at 18 months

07

Study locations

3 sites
  • Department of Renal Medicine - Aarhus University Hospital
    Aarhus, Denmark, Denmark
  • Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
    Ranica, BG 24020, Italy
  • Nephrology Department - Clínica Universidad de Navarra
    Pamplona, Spain, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2028, 16 months later.

Of 50 non-industry interventional studies with no phase under Diabetic Nephropathies, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 16 months is below that.

Counting every sponsor, half of 51 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Feb 2026 → Dec 2026, primary completion Aug 2027 → Apr 2028 and completion Aug 2027 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 8, 2025
StartEst.
Dec 1, 2026was Feb 2026
Primary completionEst.
Apr 2028was Aug 2027
CompletionEst.
Apr 2028was Aug 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first sites in Denmark and Spain
Show 2 added (1 Denmark, 1 Spain)
  • Department of Renal Medicine - Aarhus University Hospital · Aarhus, Denmark
  • Nephrology Department - Clínica Universidad de Navarra · Pamplona, Spain
Nov 19, 2026
Start date
Feb 2026→Dec 1, 2026
Nov 19, 2026
Primary completion
Aug 2027→Apr 2028
Nov 19, 2026
Study completion
Aug 2027→Apr 2028
Nov 19, 2026
Eligibility
7 criteria edited
What changed in the criteria
  • Editedmale and female subjects aged ≥ 18 years at time of screening;
  • EditedCKD stage 1G1 to 3G3 (eGFR>30 ml/min calculated by the creatinine CKD-EPI 2009 equation) with moderate or severe risk of renal disease progression (according to KDIGO 2024 CKD guidelines, G1 and G2 with albuminuria >300 mg/g, G3a with albuminuria >30 mg/g, and G3b independently of albuminuria levels);
  • Editedongoing SGLT2i treatment (e.g. canagliflozin, empagliflozin or dapagliflozin) for at least 1 month and no longer than 1 year, and stable RAS inhibitor therapy with ACE inhibitors and/or ARBs (or without RAS inhibitors in patients with specific contraindications for this medication) (Group 1) or SGLT2i-naïve subjects who have been prescribed this therapy as part of routine clinical practice prior to enrollment (Group 2).
  • EditedContraindications to MRI including claustrophobia, pregnancy or lactatingbreastfeeding, cardiac pacemakers, or other MRI-incompatible prostheses, or impossibilityinability to performundergo MRI;
  • EditedAny chronic clinical condition (e.g. history of malignancy) other than CKD and related complications that could affectmay compromise study completion of the trial or confoundaffect data interpretation;
  • EditedChronic heart failure withclass III-IV according to New York Heart Association class III-IV(NYHA) classification at the screening visit;
  • EditedIntention to become pregnant inwithin the followingnext 2 years (female patients);
Nov 19, 2026
Interventions
Changed MRI→MRI and Biochemical Analysis. Arms added: SGLT2i-naïve patients
Nov 19, 2026
Title
Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression→Renal MRI and Advanced Biochemical Markers to Predict Progression in DKD Patients Treated With SGLT2i
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    2 sites added — first sites in Denmark and Spain
    Show 2 added (1 Denmark, 1 Spain)
    • Department of Renal Medicine - Aarhus University Hospital · Aarhus, Denmark
    • Nephrology Department - Clínica Universidad de Navarra · Pamplona, Spain
    Start date Feb 2026→Dec 1, 2026
    Primary completion Aug 2027→Apr 2028
    Study completion Aug 2027→Apr 2028
    Eligibility 7 criteria edited
    What changed in the criteria
    • Editedmale and female subjects aged ≥ 18 years at time of screening;
    • EditedCKD stage 1G1 to 3G3 (eGFR>30 ml/min calculated by the creatinine CKD-EPI 2009 equation) with moderate or severe risk of renal disease progression (according to KDIGO 2024 CKD guidelines, G1 and G2 with albuminuria >300 mg/g, G3a with albuminuria >30 mg/g, and G3b independently of albuminuria levels);
    • Editedongoing SGLT2i treatment (e.g. canagliflozin, empagliflozin or dapagliflozin) for at least 1 month and no longer than 1 year, and stable RAS inhibitor therapy with ACE inhibitors and/or ARBs (or without RAS inhibitors in patients with specific contraindications for this medication) (Group 1) or SGLT2i-naïve subjects who have been prescribed this therapy as part of routine clinical practice prior to enrollment (Group 2).
    • EditedContraindications to MRI including claustrophobia, pregnancy or lactatingbreastfeeding, cardiac pacemakers, or other MRI-incompatible prostheses, or impossibilityinability to performundergo MRI;
    • EditedAny chronic clinical condition (e.g. history of malignancy) other than CKD and related complications that could affectmay compromise study completion of the trial or confoundaffect data interpretation;
    • EditedChronic heart failure withclass III-IV according to New York Heart Association class III-IV(NYHA) classification at the screening visit;
    • EditedIntention to become pregnant inwithin the followingnext 2 years (female patients);
    Interventions Changed MRI→MRI and Biochemical Analysis. Arms added: SGLT2i-naïve patients
    Title Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression→Renal MRI and Advanced Biochemical Markers to Predict Progression in DKD Patients Treated With SGLT2i
    + 5 other changes: index terms, verification date, responsible party, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07270198
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Anna Caroli, PhD
Contact
anna.caroli@marionegri.it
+390354535381
Giuseppe Remuzzi, M.D.
study director · Istituto Di Ricerche Farmacologiche Mario Negri

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion